Almac has completed a major investment in its Craigavon facility, tripling its -15°C to -25°C secondary packaging capabilities and doubling ultra-low storage capacity to support soaring demand for advanced therapies like cell and gene treatments. Alongside expanded cold chain packaging and a new cold chain management centre, the upgrades include enhanced label printing and packaging design facilities.

These developments position Almac to meet rising global demand for precise, compliant cold chain logistics in clinical trials, reinforcing its role as a partner of choice for biopharmaceutical companies navigating increasingly complex manufacturing and supply challenges.

Read the full article to see how Almac is future-proofing clinical supply chains.